Intraday Alerts
FONT-SIZE Plus   Neg

Gilead Sciences Inc. (GILD) Has Gapped Open Sharply Lower On Study Results

Trade GILD now with 

Gilead Sciences Inc. (GILD: Quote) announced Friday morning that the majority of hepatitis C genotype 1 patients with a prior "null" response to an interferon-containing regimen enrolled in the ongoing ELECTRON study experienced viral relapse within four weeks of completing 12 weeks of treatment with GS-7977 plus ribavirin.

Gilead Sciences has gapped open sharply lower Friday and is now down 8.81 at $46.00 on above average volume. The stock has dropped below a range at the highs of the year and has set a one-month low.

Click here to receive FREE breaking news email alerts for Gilead Sciences Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback:

Business News

comments powered by Disqus